Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study.
Alessandro RizzoMassimiliano SalatiGiorgio FregaValeria MerzFrancesco CaputoAlessandro Di FedericoAndrea PalloniRiccardo CarloniAngela Dalia RicciGennaro Gadaleta-CaldarolaCarlo MessinaAndrea SpallanzaniFabio GelsominoStefania BenattiGabriele LuppiDavide MelisiMassimo DominiciGiovanni BrandiPublished in: Medicina (Kaunas, Lithuania) (2022)
The results of this real-world study suggest that for patients aged ≥ 70 years, 2L could be equally effective for younger patients with survival outcomes aligned to those from the ABC-06 and NIFTY trials. The delivery of 2L should be carefully evaluated and monitored in this patient subset.